Recruiting

MPARFIBVHVestibular Function, Brain Imaging, and Blood Biomarkers in Bilateral Vestibular Hypofunction

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to observe and understand the impact of Bilateral Vestibular Hypofunction on your vestibular function, brain imaging, and blood biomarkers, using a questionnaire called the Dizziness Handicap Inventory to assess your perceived vestibular disability.

What is being collected

Diagnostic Test Data

+ diagnosticTest Data

Collected at a single point in time - Cross-sectional
Diagnostic TestDNA Samples
Who is being recruted

Ear Diseases+6

+ Labyrinth Diseases

+ Nervous System Diseases

Over 16 Years
+11 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: October 2024
See protocol details

Summary

Principal SponsorShanghai 6th People's Hospital
Study ContactYuchen Jin, Master of MedicineMore contacts
Last updated: July 16, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: October 11, 2024

Actual date on which the first participant was enrolled.

This is a prospective, multicenter, cross-sectional observational study designed to investigate the clinical, vestibular, neuroimaging, biochemical, and patient-reported characteristics associated with bilateral vestibular hypofunction (BVH). The study will recruit patients with BVH and age-matched healthy controls from five medical centers in China. The planned total sample size is approximately 120 participants, including about 80 patients with BVH and 40 healthy controls. The main objective of the study is to clarify the relationships among vestibular function, brain structure and function, biochemical variables, patient-reported symptoms, quality of life, and the severity of BVH. The study will also examine patterns of brain activity, functional connectivity, and diffusion-related microstructural changes using resting-state functional magnetic resonance imaging (rs-fMRI), diffusion tensor imaging (DTI), and diffusion kurtosis imaging (DKI). By integrating these assessments, the study aims to identify clinical and biological factors that may be associated with disease severity and functional impairment in BVH. After providing written informed consent, eligible participants will undergo collection of demographic and clinical information, including age, sex, education, blood pressure, height, weight, and medical history. Participants will then complete a series of vestibular function assessments, neuroimaging examinations, clinical symptom scales, and laboratory tests. The study is observational and cross-sectional; no investigational drug, device, surgical procedure, or therapeutic intervention will be assigned as part of the study. Vestibular function will be assessed using several complementary tests. Videonystagmography will be used to record and evaluate eye movements, including spontaneous nystagmus, gaze, saccade, and smooth pursuit eye movements. Caloric testing will be used to evaluate bilateral vestibular responsiveness and symmetry. Sinusoidal harmonic acceleration testing will assess vestibulo-ocular reflex performance during rotational stimulation. Video head impulse testing will assess dynamic semicircular canal function. Vestibular evoked myogenic potentials will be used to evaluate otolith-related vestibular function, and sensory organization testing will assess balance control under different sensory conditions. Neuroimaging will include anatomical magnetic resonance imaging, resting-state functional magnetic resonance imaging, diffusion tensor imaging, and diffusion kurtosis imaging. During magnetic resonance imaging, participants will be instructed to remain still, relax, breathe steadily, keep their eyes closed while remaining awake, and avoid intentional cognitive tasks. Anatomical imaging will be used to screen for intracranial structural abnormalities. Resting-state functional magnetic resonance imaging will be used to examine spontaneous brain activity and functional connectivity. Diffusion tensor imaging and diffusion kurtosis imaging will be used to assess white matter integrity and microstructural tissue features. Patient-reported assessments will include standardized scales evaluating dizziness-related disability, anxiety and depression symptoms, dizziness severity, and the impact of vestibular symptoms on activities of daily living. These assessments will include the Dizziness Handicap Inventory, Hospital Anxiety and Depression Scale, Visual Analog Scale, and Vestibular Disorders Activities of Daily Living Scale. Laboratory assessments will include biochemical, metabolic, inflammatory, and anti-inflammatory markers. These measures will include lipid-related indicators, glucose metabolism-related indicators, liver and renal function-related indicators, inflammatory biomarkers, anti-inflammatory biomarkers and apolipoprotein E genotyping, according to the study protocol. The primary analyses will focus on the relationships between BVH and multimodal objective measures, including neuroimaging indicators and vestibular function test results. Secondary analyses will evaluate associations involving patient-reported scales and laboratory variables. Neuroimaging data will be processed using established software platforms for functional and diffusion imaging analysis. Statistical analyses will be used to compare patients and controls and to explore associations between vestibular function, neuroimaging measures, laboratory biomarkers, symptom burden, and BVH severity. Participant safety will be monitored throughout the study. Participants may withdraw or be withdrawn from the study if they experience an allergic reaction, a serious adverse event, or another condition judged by the investigators to make continued participation unsuitable. The study has received ethics approval from the Ethics Committee of Shanghai Sixth People's Hospital and will be conducted in accordance with applicable ethical requirements. Written informed consent will be obtained before enrollment.

NCT07709143
Principal SponsorShanghai 6th People's Hospital
Study ContactYuchen Jin, Master of MedicineMore contacts
Last updated: July 16, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

120 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 16 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Ear DiseasesLabyrinth DiseasesNervous System DiseasesNeurologic ManifestationsOtorhinolaryngologic DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsVestibular DiseasesBilateral Vestibulopathy

Criteria

3 inclusion criteria required to participate
Patients meeting the diagnostic criteria for bilateral vestibulopathy (BVP) and presbyvestibulopathy (PVP)

Sex unrestricted, age over 16 years old

Participants or their legal representatives, who comprehensively understand the research purpose, demonstrate sufficient compliance with the study protocol, have the ability to communicate and cooperate, and have signed the informed consent form

8 exclusion criteria prevent from participating
Clinically significant head movement restrictions

Individuals with contraindications for MRI, including cardiac pacemakers, implanted electronic devices, claustrophobia, metallic implants incompatible with magnetic resonance imaging and medications potentially compromising MRI scan safety

Participation in alternative pharmaceutical or medical device clinical trials within the preceding 3-month period

Presence of severe cardiovascular or systemic medical conditions, organ dysfunction, or significant mobility impairments

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital

Shanghai, ChinaOpen shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital in Google Maps
Recruiting
One Study Center
MPARFIBVH | Vestibular Function, Brain Imaging, and Blood Biomarkers in Bilateral Vestibular Hypofunction | PatLynk